Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-01-08 @ 4:04 AM
Study NCT ID:
NCT05048134
Status:
TERMINATED
Last Update Posted:
2024-09-19
First Post:
2021-08-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-23
Completion Date Type:
ACTUAL
First Submit Date:
2021-08-31
First Submit QC Date:
None
Study First Post Date:
2021-09-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-17
Last Update Post Date:
2024-09-19
Last Update Post Date Type:
ACTUAL